Immunomodulatory aspects of photodynamic therapy

Bibliography

• DOUGHERTY TJ: Activated dyes as anti-tumor agents. J. Natl. Cancer Inst. (1974) 51:1333–1336.
   Google Scholar
• LEVY JG: Photosensitizers in photodynamic therapy. Semin. Oncol. (1994) 21:4–10.
   PubMed Web of Science ®Google Scholar
• LEVY JG: Photodynamic therapy. Trends Biotech. (1995)13:14–17.
   PubMed Web of Science ®Google Scholar
• PASS HI: Photodynamic therapy in oncology: mecha-nisms and clinical use. J. Natl. Cancer Inst. (1993) 85:443–456.
   PubMed Web of Science ®Google Scholar
• HENDERSON BW, DOUGHERTY TJ: How does photody- namic therapy work? Photochem. PhotobioL (1992) 55:145–157.
   PubMed Web of Science ®Google Scholar
• •A comprehensive review of the cellular, tissue and antitu-mour effects of different photosensitisers.
   Google Scholar
• KENNEDY JC, POTTIER RH, PROSS DC: Photodynamic therapy with endogeous protoporphyrin IX: basic principles and present clinical experience. .1 Photo-chem. Photobiol. (1990) 6:143–148.
   PubMed Web of Science ®Google Scholar
• RICHTER AM, KELLY B, CHOW J et al.: Preliminary stud-ies on a more effective phototoxic agent than hemato-porphyrin. Natl. Cancer Inst. (1987) 79:1327–1332.
   Google Scholar
• GOMER CJ, FERRARIO A, HAYASHI N et al.: Molecular, cellular and tissue responses following photodynamic therapy. Lasers Surg. Med. (1988) 8:450–463.
   PubMed Web of Science ®Google Scholar
• GOMER CJ, RUCKER N, FERRARIO A, WONG S: Properties and applications of photodynamic therapy. Radiat. Res. (1989) 120:1–18.
   PubMed Web of Science ®Google Scholar
• •A summary of porphyrin photochemistry and cellular re-sponses to PDT at the molecular level.
   Google Scholar
• AGRARWAL ML, CLAY ME, HARVEY EJ et al.: Photody-namic therapy induces rapid cell death by apoptosis in L5178Y mouse lymphoma cells. Cancer Res. (1991) 51:5993–5996.
   PubMed Web of Science ®Google Scholar
• GRANVILLE DJ, LEVY JG, HUNT DWC: Photodynamictherapy induces the activation of multiple proteases involved in the apoptotic cell death pathway. Cell Death Different. (1997) 4:623–628.
   PubMed Web of Science ®Google Scholar
• •The first study to describe the activation of the apoptosis-associated caspase pathway in cells treated with a porphyrin photosensitiser and light.
   Google Scholar
• KROEMER G, ZAMZAMI, SUSIN SA: Mitochondrial con-trol of apoptosis. ImmunoL Today (1997) 18:44–51.
   PubMedGoogle Scholar
• SEPAROVIC D, HE J, OLEINICK NL: Ceramide generation in response to photodynamic treatment of L5178Y mouse lymphoma cells. Cancer Res. (1997) 57:1717–1721.
   PubMed Web of Science ®Google Scholar
• ANDERSON C, HRABOVSKY S, MCKINLEY Y et al.: Phthalocyanine photodynamic therapy: disparate ef-fects of pharmacologic inhibitors on cutaneous photo-sensitivity and on tumor regression. Photochem. Photobiol. (1997) 65:895–901.
   PubMed Web of Science ®Google Scholar
• TAO, J, SANGHERA JS, PELECH SL et al.: Stimulation of stress-activated protein kinase and p38 HOG1 kinase in murine keratinocytes following photodynamic therapy with benzoporphyrin derivative. .1 BioL Chem. (1996) 271:27107–27115.
   Google Scholar
• SHUMAKER BP, HETZEL FW: Clinical laser photody-namic therapy in the treatment of bladder cancer. Pho-tochem. PhotobioL (1987) 46:899–901.
   PubMed Web of Science ®Google Scholar
• NSEYO UO, WHALEN RK, DUNCAN MR et al.: Urinary cy-tokines following photodynamic therapy for bladder cancer. A preliminary report. Urology (1990) 36:167–171.
   Google Scholar
• HERMAN S, KALECHMAN Y, GAFTER U et al.: Photofrin IIinduces cytokine secretion by mouse spleen cells and human peripheral mononuclear cells. Immunophar-macology (1996) 31:195–204.
   PubMedGoogle Scholar
• HUNT DWC, SORRENTI RA, SMITS CB, LEVY JG: Pho-tofrin®, but not benzoporphyrin derivative, stimulates hematopoiesis in the mouse. Immunopharmacology (1993) 26:203–212.
   PubMedGoogle Scholar
• HUNT DWC, JIANG H, LEVY JG: Photofrin® increases murine spleen cell transferrin receptor expression and responsiveness to recombinant myeloid and erythroid growth factors. Immunopharmacology (1997) (In Press.)
   Google Scholar
• KORBELIK M, KROSL G: Enhanced macrophage cyto-toxicity against tumor cells treated with photody-namic therapy. Photochem, Photobiol, (1994) 60:497–502.
   PubMed Web of Science ®Google Scholar
• YAMAMOTO N, SERY TW, HOOBER JK et al.: Effective-ness of Photofrin II in activation of macrophages and in vitro killing of retinoblastoma cells. Photochem. Pho-tobiol. (1994) 60:160–164.
   PubMed Web of Science ®Google Scholar
• HENDERSON BW, DONOVAN JM: Release of prostaglan-din Ey from cells by photodynamic treatment in vitro. Cancer Res, (1989) 49:6896–6900.
   PubMed Web of Science ®Google Scholar
• EVANS S, MATTHEWS W, PERRY R et al.: Effect of photo-dynamic therapy on tumor necrosis factor production by murine macrophages. J. Nall, Cancer Inst. (1990) 82:34–39.
   PubMed Web of Science ®Google Scholar
• GRUNER S, VOLK H, NOACK F et al.: Inhibition of HLA-DR antigen expression and of the mixed leukocyte re-action by photochemical treatment. Tissue Antigens (1986) 27:147–154.
   PubMed Web of Science ®Google Scholar
• KRUTMAN J, ATHAR M, MENDEL DB et al.: Inhibition ofthe high affinity Fc receptor (FcyRO on human mono-cytes by porphyrin photosensitization is highly spe-cific and mediated by the generation of superoxide radicals. J. Biol. Chem. (1989) 264:11407–11413.
   PubMed Web of Science ®Google Scholar
• NORTH J, NEYNDORFF H, LEVY JG: Photosensitizers asvirucidal agents. J. Photochem, Photobiol, (1993) 17:99–108.
   Google Scholar
• ALLISON BA, PRITCHARD PH, LEVY JG: Evidence forlow-density lipoprotein uptake of benzoporphyrin de-rivative. Br, J. Cancer (1994) 69:833–839.
   PubMed Web of Science ®Google Scholar
• OBOCHI MOK, CANAAN AJ, JAIN AK et al.: Targeting acti-vated lymphocytes with photodynamic therapy: sus-ceptibility of mitogen-stimulated splenic lymphocytes to benzoporphyrin derivative (BPD) photosensitiza-tion. Photochem. PhotobioL (1995) 62:169–175.
   PubMed Web of Science ®Google Scholar
• CANTI G, MARELLI O, RICCI L, NICOLIN A:Haematoporphyrin-treated murine lymphocytes: in vitro inhibition of DNA synthesis and light-mediated inactivation of cells responsible for GVHR. Photochem Photobiol, (1981) 34:589–594.
   PubMed Web of Science ®Google Scholar
• HUNT DWC, JIANG H-J, LEVY JG, CHAN AH: Sensitivity of activated murine peritoneal macrophages to photody-namic killing with benzoporphyrin derivative. Photo-chem, Photobiol, (1995) 61:417–421.
   PubMed Web of Science ®Google Scholar
• STEINMAN RM: The dendritic cell system and its role in immunogenicity. Ann. Rev, ImmunoL (1991) 9:271–296.
   PubMed Web of Science ®Google Scholar
• OBOCHI MOK, RATKAY LG, LEVY JG: Prolonged skin al-lograft survival after photodynamic therapy (PDT) as-sociated with modification of donor skin antigenicity. Transplantation (1997) 63:1–8.
   PubMedGoogle Scholar
• GRUNER S, MEFFERT H, VOLK D et al.: The influence of haematoporphyrin derivative and visible light on murine skin graft survival, epidermal Langerhans cells and stimulation of the allogeneic mixed leuko-cyte reaction. Scand, J. Immunol, (1985) 21:267–273.
   PubMed Web of Science ®Google Scholar
• HUNT DWC, KING DE, LEVY JG: Influence of benzopor-phyrin derivative monoacid ring A (BPD-MA, vertepor-fin) on murine dendritic cells. Proceedings of Optical Methods for Tumour Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy Soc, Photo-Opt, Instr, Eng. (1997) 2972:110–120.
   Google Scholar
• ELMETS CA, BOWEN KD: Immunological suppression in mice treated with haematoporphyrin derivative photoradiation. Cancer Res. (1986) 6:1608–1611.
   Google Scholar
• LYNCH DH, HADDAD S, KING VJ et al.: Systemic immu-nosuppression induced by photodynamic therapy (PDT) is adoptively transferred by macrophages. Pho-tochem, Photobiol, (1989) 49:453–458.
   PubMed Web of Science ®Google Scholar
• QIN B, SELMAN SH, PAYNE KM et al.: Enhanced skin allo-graft survival after photodynamic therapy. Associa-tion with lymphocyte inactivation and macrophage stimulation. Transplantation (1993) 56:1481–1486.
   Google Scholar
• RICHTER AM, JAIN AK, OBOCHI M et al.: Activation of benzoporphyrin derivative in the circulation of mice without skin photosensitivity. Photochem, PhotobioL (1994) 59:350–355.
   PubMed Web of Science ®Google Scholar
• LEONG S, CHAN AH, LEVY JG, HUNT DWC: Transcutane-ous photodynamic therapy alters the development of an adoptively transferred form of murine experimen-tal autoimmune encephalomyelitis. Photochem, Photo-biol. (1996) 64:751–757.
   PubMed Web of Science ®Google Scholar
• CHOWDHARY RK, RATKAY LG, NEYNDORFF HC et al.:The use of transcutaneous photodynamic therapy in the prevention of adjuvant-enhanced arthritis in MRL/lpr mice. Clin, ImmunoL ImmunopathoL (1994) 72:255–263.
   PubMedGoogle Scholar
• RATKAY, LG, CHOWDHARY RK, NEYNDORFF HC et al.: Photodynamic therapy: a comparison with other im-munomodulatory treatments of adjuvant-enhanced arthritis in MRL/lpr mice. Din, ImmunoL Immunopa-thol. (1994) 95:373–377.
   Web of Science ®Google Scholar
• SIMKIN GO, KING DE, LEVY JG, CHAN AH, HUNT DWC: Inhibition of contact hypersensitivity with different analogs of benzoporphyrin derivative. Immunophar-macology (1997) 37:221–230.
   PubMedGoogle Scholar
• SCHMITT DA, OWEN-SCHAUB, ULLRICH SE: Effect of IL-12 on immune suppression and suppressor cell induction by ultraviolet radiation. J. Immunol. (1995) 154:5114–5120.
   PubMed Web of Science ®Google Scholar
• SCHWARZ A, GRABBE S, ARAGANE Y et al.: Interleukin-12 prevents ultraviolet B-induced local immunosup-pression and overcomes UVB-induced tolerance. J. In-vest. Dermatol. (1996) 106:1187–1191.
   Web of Science ®Google Scholar
• GOLLNICK SO, LIU W, OWCZARCZAK, MUSSER DA, HENDERSON BW: Altered expression of interleukin 6 and interleukin 10 as a result of photodynamic ther-apy in vivo. Cancer Res. (1997) 57:3904–3909.
   PubMed Web of Science ®Google Scholar
• ••This work examines the relationships between tumour andskin cytokine production and forwards data to account for the ability of Photofrin®-mediated PDT to concomitantly en-hance antitumour immunity under conditions that inhibit CHS responses.
   Google Scholar
• D'ANDREA A, ASTE-AMEZAGA M, VALIANTE NM et al.: In-terleukin 10 (IL-10) inhibits human lymphocyte interferon y-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. Exp. Med. (1993) 178:1041–1048.
   Google Scholar
• ENK AH, ANGELONI VL, UDEY MC, KATZ SI: Inhibition ofLangerhans cell antigen-presenting function by IL-10. A role for IL-10 in induction of tolerance. J. Immunol. (1993) 151:2390–2398.
   PubMed Web of Science ®Google Scholar